Doherty P C, Wisler P A
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
Life Sci. 1994;54(7):507-14. doi: 10.1016/0024-3205(94)00410-2.
Quinelorane, a highly selective D2 dopamine agonist, was assessed for its ability to induce the penile erection/stretch-yawn syndrome. Quinelorane (0.1-100 micrograms/kg s.c.) or saline vehicle was administered to adult male Sprague-Dawley rats just prior to a 30 min. observation period. Significant dose-related increases in erections were observed in the drug treated animals at 3-100 micrograms/kg. Yawning was also increased at 3-100 micrograms/kg, with highest levels occurring at 10 micrograms/kg. Defecation was stimulated between 10 and 100 micrograms/kg. The stimulatory effects of 30 micrograms/kg of quinelorane on erection, yawning and defecation were blocked by haloperidol (0.1-0.3 mg/kg) but not by domperidone (0.1-1.0 mg/kg). No significant effects of quinelorane on seminal emission were observed. These findings indicate that in addition to its stimulatory effects on sexual activity, quinelorane also acts on D2 receptors in the central nervous system to stimulate erection in the penile erection/stretch-yawn model.